2017
DOI: 10.1016/j.oraloncology.2016.12.016
|View full text |Cite|
|
Sign up to set email alerts
|

Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
103
0
4

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 101 publications
(114 citation statements)
references
References 65 publications
3
103
0
4
Order By: Relevance
“…Histologic subtypes of salivary gland cancers can be segregated by the expression of specific molecular markers and may accordingly respond differently to conventional and targeted chemotherapeutic agents. 2 For instance, ACC tends to express the receptor tyrosine kinase (RTK) c-Kit and is known to be poorly responsive to not only conventional chemotherapy 3 but also TKIs with activity against c-Kit, such as imatinib 4 and dasatinib. 5 In contrast, a recent retrospective review of patients with SDC suggested a benefit to treatment with combined carboplatin and paclitaxel.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Histologic subtypes of salivary gland cancers can be segregated by the expression of specific molecular markers and may accordingly respond differently to conventional and targeted chemotherapeutic agents. 2 For instance, ACC tends to express the receptor tyrosine kinase (RTK) c-Kit and is known to be poorly responsive to not only conventional chemotherapy 3 but also TKIs with activity against c-Kit, such as imatinib 4 and dasatinib. 5 In contrast, a recent retrospective review of patients with SDC suggested a benefit to treatment with combined carboplatin and paclitaxel.…”
Section: Discussionmentioning
confidence: 99%
“…9 Therefore, it only rarely expresses estrogen or progesterone receptors, but has been associated with expression of HER2 and AR, both of which might be markers for response to targeted therapies. 2 Retrospective studies have suggested that targeting HER2 with trastuzumab may be of benefit in HER2-expressing SDC, 10 and interim results from a prospective phase II trial of docetaxel plus trastuzumab were encouraging. 11 Furthermore, a recent case report suggested that trastuzumab emtansine (T-DM1) may have utility after trastuzumab failure.…”
Section: Discussionmentioning
confidence: 99%
“…The approach to the incurable recurrent or metastatic patient is unclear, due to the great biological heterogeneity, which is highly histology‐dependent. Responses to systemic agents in unselected patients are generally modest . As randomized controlled studies are lacking, treatment selection in SGCs should be made on a more personalized approach.…”
Section: Introductionmentioning
confidence: 99%
“…Inoperable or metastatic ACCs can have an indolent course, and watchful waiting is the most common approach . When treatment is warranted, a response rate of 15% to 70% is achieved with cisplatin and 15.4% with vinorelbine .…”
Section: Introductionmentioning
confidence: 99%
“…For instance, ACC's indolent behavior is explained by its scarce genetic instability whereas salivary duct carcinomas are characterized by a high mutation rate and the expression of androgen receptor . Therefore, this latter type of PC has an aggressive clinical course yet promising trials are being conducted using androgen‐deprivation therapy . Even more recently, it has been demonstrated how programmed death‐1 ligand‐1 (PD‐L1) expression can significantly predict outcomes and the risk of developing DM .…”
Section: Discussionmentioning
confidence: 99%